<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01187550</url>
  </required_header>
  <id_info>
    <org_study_id>27709</org_study_id>
    <nct_id>NCT01187550</nct_id>
  </id_info>
  <brief_title>Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®</brief_title>
  <official_title>A Phase IV Open-label Study of Predictive Markers in Growth Hormone Deficient Pre-pubertal Children Treated With Saizen®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Serono Co., Ltd., China</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck KGaA</source>
  <brief_summary>
    <textblock>
      This is an open-label, prospective, multicentric, non-comparative, non-randomized Phase IV
      interventional study in which subjects pre-diagnosed with Growth Hormone Deficiency (GHD)
      were treated for 4 weeks with Saizen to compare the response between GHD children born
      appropriate for gestational age (AGA) and those born small for gestation age (SGA) after 4
      weeks of Saizen therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The response to growth hormone (GH) treatment, short-term as well as long-term, displays
      considerable inter individual variability. This is particularly evident for the endpoint of
      paediatric GH administration, that is (i.e.) the growth response, which is pronounced in
      children who are affected by GHD. This is an open-label, multicentric study in which subjects
      pre-diagnosed with GHD were treated for 4 weeks with Saizen. Two hundred fourteen GHD
      evaluable pre-pubertal subjects were planned to be recruited in approximately 9 sites in
      China. Demographic data, medical history, tanner stage, physical examination, body weight,
      height, bone age measurement, body mass index, review of baseline medications and procedures
      and blood sampling were performed at baseline visit, end of treatment visit (week 4) and at 4
      week follow-up visit.

      OBJECTIVES

      Primary objective:

        -  To compare the response between GHD children born AGA and those born SGA after 4 weeks
           of Saizen therapy

      Secondary Objectives:

        -  To explore the contribution of selected genes to the phenotype of GHD children

        -  To explore the impact of gene polymorphisms on the levels of specific serum biomarkers
           in GHD children after 4 weeks of Saizen therapy

        -  To explore the relationships between changes in gene expression and changes in serum
           biomarkers after 4 weeks of Saizen therapy and the spectrum of gene polymorphisms in GHD
           children
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date>April 2009</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Serum Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) Levels at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) was calculated as logarithm (log) 10 actual value of IGF-1 - log 10 (mean reference value of IGF-1) divided by log10 reference standard deviation of IGF-1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Insulin Like Growth Factor Binding Protein-3 (IGFBP-3) Levels at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Glucose at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Insulin at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) Test at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>HOMA-IR is used to assess insulin resistance and calculated by an empirical mathematical formula based on fasting plasma glucose and fasting plasma insulin levels. HOMA-IR = fasting plasma insulin (picomole/liter [pmol/L]) * fasting plasma glucose (millimole/liter [mmol/L]) divided by 22.5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lipid Profile at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Total cholesterol, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol and triglycerides levels were evaluated.</description>
  </secondary_outcome>
  <enrollment type="Actual">214</enrollment>
  <condition>Dwarfism, Pituitary</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human growth hormone (r-hGH)</intervention_name>
    <description>Recombinant human growth hormone (r-hGH) administered at dose of 0.033 milligram/kilogram (mg/kg) body weight (0.1 International Unit [IU]/kg body weight) per day by subcutaneous injection.</description>
    <other_name>Saizen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects with documented pre-established diagnosis of GHD with a GH
             peak response of &lt;10 microgram/liter (mcg/L) with 2 GH stimulation tests, without
             priming with estradiol

          -  Subjects with SGA defined as birth weight and/or length at least 2 standard deviations
             (SDs) below the mean for gestational age

          -  Subjects with prepubertal status according to Tanner

          -  Subjects with pre-established history of normal thyroid function or adequate
             substitution for at least 3 months

          -  Subjects with weight for stature within the population specific normal range (&gt;5th and
             &lt;95th percentiles) for gender

          -  Subjects with willingness and ability to comply with the protocol for the duration of
             the study

          -  Subjects whose parents or guardians written informed consent given before any
             study-related procedure that was not part of the subjects normal medical care, with
             the understanding that the subject or parent/guardian might withdraw consent at any
             time without prejudice to future medical care. If the child was old enough to read and
             write, a separate assent form was given

        Exclusion Criteria:

          -  Subjects who acquired GHD due to central nervous system tumor, trauma, infection,
             infiltration (documented by imaging), and history of irradiation or cranial surgery

          -  Subjects with previous treatment with GH, growth hormone releasing hormone (GHRH),
             anabolic steroids or any treatment affecting growth

          -  Subjects who had previous treatment with corticosteroids, except in case of topical or
             inhaled corticosteroid administration for atopic disease. Corticosteroids for hormonal
             substitution were also allowed if the condition and the treatment regimen had been
             stable for at least 3 months

          -  Subjects with severe associated pathology affecting growth such as malnutrition,
             malabsorption, or bone dysplasia

          -  Subjects with chronic severe kidney disease

          -  Subjects with chronic severe liver disease

          -  Subjects with chronic infectious disease

          -  Subjects with acute or severe illness during the previous 6 months

          -  Subjects with significant concomitant illness that would interfere with participation
             or assessment in this study

          -  Subjects who had active malignancy (except non-melanomatous skin malignancies that had
             undergone surgical excision and/or biopsy, diagnosis and treatment to resolution)

          -  Subjects with history or active idiopathic intra-cranial hypertension (benign
             intracranial hypertension or pseudo-tumor cerebri)

          -  Subjects with diabetes mellitus type I &amp; II

          -  Subjects with any autoimmune disease

          -  Subjects who had previous screening failure in this study

          -  Subjects who had used an investigational drug or participated in another clinical
             study within the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Serono Co., Ltd., China</affiliation>
  </overall_official>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2010</study_first_submitted>
  <study_first_submitted_qc>August 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2010</study_first_posted>
  <results_first_submitted>May 9, 2012</results_first_submitted>
  <results_first_submitted_qc>June 28, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 7, 2012</results_first_posted>
  <last_update_submitted>January 20, 2014</last_update_submitted>
  <last_update_submitted_qc>January 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dwarfism, pituitary</keyword>
  <keyword>Growth hormone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pituitary Diseases</mesh_term>
    <mesh_term>Dwarfism</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Out of 214 participants enrolled in the study, 1 participant could not be categorized as appropriate for gestational age (AGA) or small for gestational age (SGA) since weight and height at birth was not available.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Appropriate for Gestational Age (AGA)</title>
          <description>Participants in AGA group received Saizen (recombinant human growth hormone, r-hGH) subcutaneously (sc) at the daily dose of 0.033 milligram/kilogram (mg/kg) body weight for 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Small for Gestational Age (SGA)</title>
          <description>Participants in SGA group received Saizen (r-hGH) sc at the daily dose of 0.033 mg/kg body weight for 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="169"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Appropriate for Gestational Age (AGA)</title>
          <description>Participants in AGA group received Saizen (recombinant human growth hormone, r-hGH) subcutaneously (sc) at the daily dose of 0.033 milligram/kilogram (mg/kg) body weight for 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Small for Gestational Age (SGA)</title>
          <description>Participants in SGA group received Saizen (r-hGH) sc at the daily dose of 0.033 mg/kg body weight for 4 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="175"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="205"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Out of a total of 213 participants, data for baseline measure (age) was available for only 205 participants who were treated.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.52" spread="3.844"/>
                    <measurement group_id="B2" value="9.39" spread="4.349"/>
                    <measurement group_id="B3" value="10.35" spread="3.931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Out of a total of 213 participants, data for baseline measure (gender) was available for only 205 participants who were treated.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Serum Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) Levels at Week 4</title>
        <description>Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) was calculated as logarithm (log) 10 actual value of IGF-1 - log 10 (mean reference value of IGF-1) divided by log10 reference standard deviation of IGF-1.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>The intent-to-treat (ITT) population set included all the participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Appropriate for Gestational Age (AGA)</title>
            <description>Participants in AGA group received Saizen (recombinant human growth hormone, r-hGH) subcutaneously (sc) at the daily dose of 0.033 milligram/kilogram (mg/kg) body weight for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Small for Gestational Age (SGA)</title>
            <description>Participants in SGA group received Saizen (r-hGH) sc at the daily dose of 0.033 mg/kg body weight for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) Levels at Week 4</title>
          <description>Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) was calculated as logarithm (log) 10 actual value of IGF-1 - log 10 (mean reference value of IGF-1) divided by log10 reference standard deviation of IGF-1.</description>
          <population>The intent-to-treat (ITT) population set included all the participants who received at least 1 dose of study medication.</population>
          <units>nanogram/millilter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.04" spread="2.341"/>
                    <measurement group_id="O2" value="-2.22" spread="2.390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="1.358"/>
                    <measurement group_id="O2" value="0.85" spread="1.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.194</p_value>
            <method>Wilcoxon rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Insulin Like Growth Factor Binding Protein-3 (IGFBP-3) Levels at Week 4</title>
        <time_frame>Baseline and Week 4</time_frame>
        <population>ITT population set included all the participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Appropriate for Gestational Age (AGA)</title>
            <description>Participants in AGA group received Saizen (recombinant human growth hormone, r-hGH) subcutaneously (sc) at the daily dose of 0.033 milligram/kilogram (mg/kg) body weight for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Small for Gestational Age (SGA)</title>
            <description>Participants in SGA group received Saizen (r-hGH) sc at the daily dose of 0.033 mg/kg body weight for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Insulin Like Growth Factor Binding Protein-3 (IGFBP-3) Levels at Week 4</title>
          <population>ITT population set included all the participants who received at least 1 dose of study medication.</population>
          <units>microgram/mL (mcg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.16" spread="1.386"/>
                    <measurement group_id="O2" value="2.57" spread="1.525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.869"/>
                    <measurement group_id="O2" value="0.51" spread="0.805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.752</p_value>
            <method>Wilcoxon rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Glucose at Week 4</title>
        <time_frame>Baseline and Week 4</time_frame>
        <population>ITT population set included all the participants who received at least 1 dose of study medication. Here ‘N’ (Number of participants analyzed) signified those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Appropriate for Gestational Age (AGA)</title>
            <description>Participants in AGA group received Saizen (recombinant human growth hormone, r-hGH) subcutaneously (sc) at the daily dose of 0.033 milligram/kilogram (mg/kg) body weight for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Small for Gestational Age (SGA)</title>
            <description>Participants in SGA group received Saizen (r-hGH) sc at the daily dose of 0.033 mg/kg body weight for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Glucose at Week 4</title>
          <population>ITT population set included all the participants who received at least 1 dose of study medication. Here ‘N’ (Number of participants analyzed) signified those participants who were evaluable for this measure.</population>
          <units>millimole/liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.83" spread="0.471"/>
                    <measurement group_id="O2" value="4.46" spread="1.106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.578"/>
                    <measurement group_id="O2" value="0.22" spread="0.886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.710</p_value>
            <method>Wilcoxon rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Insulin at Week 4</title>
        <time_frame>Baseline and Week 4</time_frame>
        <population>ITT population set included all the participants who received at least 1 dose of study medication. Here ‘N’ (Number of participants analyzed) signified those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Appropriate for Gestational Age (AGA)</title>
            <description>Participants in AGA group received Saizen (recombinant human growth hormone, r-hGH) subcutaneously (sc) at the daily dose of 0.033 milligram/kilogram (mg/kg) body weight for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Small for Gestational Age (SGA)</title>
            <description>Participants in SGA group received Saizen (r-hGH) sc at the daily dose of 0.033 mg/kg body weight for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Insulin at Week 4</title>
          <population>ITT population set included all the participants who received at least 1 dose of study medication. Here ‘N’ (Number of participants analyzed) signified those participants who were evaluable for this measure.</population>
          <units>picomole/L (pmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.17" spread="74.575"/>
                    <measurement group_id="O2" value="23.58" spread="14.892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.08" spread="81.674"/>
                    <measurement group_id="O2" value="12.04" spread="32.389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.265</p_value>
            <method>Wilcoxon rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) Test at Week 4</title>
        <description>HOMA-IR is used to assess insulin resistance and calculated by an empirical mathematical formula based on fasting plasma glucose and fasting plasma insulin levels. HOMA-IR = fasting plasma insulin (picomole/liter [pmol/L]) * fasting plasma glucose (millimole/liter [mmol/L]) divided by 22.5.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>ITT population set included all the participants who received at least 1 dose of study medication. Here ‘N’ (Number of participants analyzed) signified those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Appropriate for Gestational Age (AGA)</title>
            <description>Participants in AGA group received Saizen (recombinant human growth hormone, r-hGH) subcutaneously (sc) at the daily dose of 0.033 milligram/kilogram (mg/kg) body weight for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Small for Gestational Age (SGA)</title>
            <description>Participants in SGA group received Saizen (r-hGH) sc at the daily dose of 0.033 mg/kg body weight for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) Test at Week 4</title>
          <description>HOMA-IR is used to assess insulin resistance and calculated by an empirical mathematical formula based on fasting plasma glucose and fasting plasma insulin levels. HOMA-IR = fasting plasma insulin (picomole/liter [pmol/L]) * fasting plasma glucose (millimole/liter [mmol/L]) divided by 22.5.</description>
          <population>ITT population set included all the participants who received at least 1 dose of study medication. Here ‘N’ (Number of participants analyzed) signified those participants who were evaluable for this measure.</population>
          <units>pmol/L*mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.91" spread="15.662"/>
                    <measurement group_id="O2" value="5.06" spread="3.290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.96" spread="18.458"/>
                    <measurement group_id="O2" value="2.48" spread="6.527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.308</p_value>
            <method>Wilcoxon rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lipid Profile at Week 4</title>
        <description>Total cholesterol, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol and triglycerides levels were evaluated.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>ITT population set included all the participants who received at least 1 dose of study medication. Here ‘N’ (Number of participants analyzed) signified those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Appropriate for Gestational Age (AGA)</title>
            <description>Participants in AGA group received Saizen (recombinant human growth hormone, r-hGH) subcutaneously (sc) at the daily dose of 0.033 milligram/kilogram (mg/kg) body weight for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Small for Gestational Age (SGA)</title>
            <description>Participants in SGA group received Saizen (r-hGH) sc at the daily dose of 0.033 mg/kg body weight for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lipid Profile at Week 4</title>
          <description>Total cholesterol, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol and triglycerides levels were evaluated.</description>
          <population>ITT population set included all the participants who received at least 1 dose of study medication. Here ‘N’ (Number of participants analyzed) signified those participants who were evaluable for this measure.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Total Cholesterol)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.16" spread="0.752"/>
                    <measurement group_id="O2" value="4.22" spread="0.833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (HDL-Cholesterol)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="0.452"/>
                    <measurement group_id="O2" value="1.59" spread="0.443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (LDL-Cholesterol)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.18" spread="0.672"/>
                    <measurement group_id="O2" value="2.19" spread="0.709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (Triglycerides)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" spread="0.527"/>
                    <measurement group_id="O2" value="1.02" spread="0.638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4 (Total Cholesterol)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.601"/>
                    <measurement group_id="O2" value="-0.03" spread="0.612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4 (HDL-Cholesterol)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.317"/>
                    <measurement group_id="O2" value="0.02" spread="0.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4 (LDL-Cholesterol)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.546"/>
                    <measurement group_id="O2" value="0.02" spread="0.502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4 (Triglycerides)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.551"/>
                    <measurement group_id="O2" value="-0.09" spread="0.831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For total cholesterol: Wilcoxon rank sum test was used to calculate p-value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.078</p_value>
            <method>Wilcoxon rank sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For HDL-cholesterol: Wilcoxon rank sum test was used to calculate p-value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <method>Wilcoxon rank sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For LDL-cholesterol: Wilcoxon rank sum test was used to calculate p-value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.041</p_value>
            <method>Wilcoxon rank sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For triglycerides: Wilcoxon rank sum test was used to calculate p-value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.091</p_value>
            <method>Wilcoxon rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) are collected on an ongoing basis from day of written informed consent. All new AEs must be recorded until 4 weeks post drug administration. AEs are classified as pre-treatment, treatment-emergent and post-treatment.</time_frame>
      <desc>Pre-Treatment:Medical conditions present at initial study visit that did not worsen in severity or frequency during study;Treatment-Emergent: If onset date of AE was on or after the first dose date of the study medication; Post-Treatment: If the onset date of AE was post 4 weeks after drug administration for participants who completed the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Appropriate for Gestational Age (AGA)</title>
          <description>Participants in AGA group received Saizen (recombinant human growth hormone, r-hGH) subcutaneously (sc) at the daily dose of 0.033 milligram/kilogram (mg/kg) body weight for 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Small for Gestational Age (SGA)</title>
          <description>Participants in SGA group received Saizen (r-hGH) sc at the daily dose of 0.033 mg/kg body weight for 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Eye Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Ocular Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Injection Site Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver Function Test Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Merck KGaA Communication Center</name_or_title>
      <organization>Merck Serono, a division of Merck KGaA</organization>
      <phone>+49-6151-72-5200</phone>
      <email>service@merckgroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

